Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2003
12/18/2003US20030232888 Methods for identifying and using IKK inhibitors
12/18/2003US20030232887 Preparation and use of a stable formulation of allosteric effector compounds
12/18/2003US20030232884 New pharmaceutical formulation
12/18/2003US20030232883 N-acylamino benzyl ether derivatives
12/18/2003US20030232882 Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
12/18/2003US20030232881 Large crystals suitable for use in direct compression
12/18/2003US20030232880 For therapy of pain, fever or inflammation to inhibit prostanoid-induced smooth muscle contraction; for prophylaxis and therapy of colorectal cancer or neurodegenerative diseases
12/18/2003US20030232879 Lipid-altering compositions for the treatment of infertility
12/18/2003US20030232876 Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
12/18/2003US20030232875 Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors
12/18/2003US20030232874 Methods and compositions for the treatment of chronic lymphocytic leukemia
12/18/2003US20030232871 Crystalline parecoxib sodium
12/18/2003US20030232869 N3 alkylated benzimidazole derivatives as MEK inhibitors
12/18/2003US20030232868 Cyclic carboxylic acids as integrin antagonists
12/18/2003US20030232867 Comprises (2Z)-2-cyano-3-hydroxy-N-(4-(trifluoromethyl) phenyl)-2-hepten-6-ynamide for preventing/treating chronic rejection in a transplanted organ or tissue
12/18/2003US20030232865 1,4-Benzofused urea compounds useful in treating cytokine mediated diseases
12/18/2003US20030232864 Novel Compounds and compositions as protease inhibitors
12/18/2003US20030232863 Cathepsin cysteine protease inhibitors
12/18/2003US20030232862 Administering inhibitors of human epidermal growth factor receptor tyrosine kinase and cGMP-specific phosphodiesterase; side effects reduction
12/18/2003US20030232860 Medicine comprising dicyanopyridine derivative
12/18/2003US20030232859 Antiinflammatory agents; for treatment of rheumatoid arthritis and multiple sclerosis
12/18/2003US20030232858 Use of hydroxyeicosatetraenoic acid compounds to treat dry mouth
12/18/2003US20030232857 Side effects reduction; for treating nervous system disorders (attention deficit/hyperactivity, and cognitive decline associated with acquired immunodeficiency syndrome)
12/18/2003US20030232856 Comprises 9-aminoacridines and 4-aminoquinolines; for treatment of lupus; interleukins; immunoglobulins; drug screening
12/18/2003US20030232855 Such as N-(benzo(1,3)dioxol-5-ylmethyl)-7-methoxy-2-oxo-8-pentyloxy-1,2 -dihydroquinoline-3-carboxamide for stimulation of peripheral cell type cannabinoid receptors
12/18/2003US20030232853 Azabicyclic compounds for the treatment of disease
12/18/2003US20030232851 Viral treatment
12/18/2003US20030232850 Heterocyclic amines such as 2-benzoyl-1,3,4,9-tetrahydro-2H-pyrido(3,4-b)indole, used preferential inhibitors of fatty acid biosynthesis in bacterial systems; bactericides
12/18/2003US20030232849 N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
12/18/2003US20030232848 Pyrazole compositions
12/18/2003US20030232846 Caspase inhibitors and uses thereof
12/18/2003US20030232845 Enzyme hydrolase inhibitors such as 1-ethyl-3,7-dihydro-8-((1 R,2R)-(hydroxycyclopentyl)amino)-3-(2-hydroxyethyl)-7-((3-bromo-4 -methoxyphenyl)methyl)-1H-Purine-2,6-dione, used for physiological effects
12/18/2003US20030232844 Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2 mediated disorders
12/18/2003US20030232841 Amides such as 5-(2-(4-methylpiperazin-1-yl)-phenyl)-furan-2-carboxylic acid 4-chlorobenzylamide, used as antidepressants and for prophylaxis of headaches
12/18/2003US20030232839 Administering heterocyclic amines, as controllers of central nervous system(CNS) such as serotonin receptors
12/18/2003US20030232838 6-phenylpyrrolopyrimidinedione derivatives
12/18/2003US20030232837 17-Beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
12/18/2003US20030232836 Secondary amides such as 2-(4-(2- methoxyphenyl)-1-piperazinyl )-N-(3-methylphenyl)acetamide, used for prophylaxis of impotency
12/18/2003US20030232835 Nitrogen compounds such as tetrahydrobiopterin, used as hypotensive agents and prevention or urogenital disorders due nitric oxide synthase (NOS)
12/18/2003US20030232832 Nitrogen compounds such as N-(3-Aminopropyl)-N-(1-(3-benzyl-4 -oxo-3,4-dihydropyrrolo(2,1-f)(1,2,4)-triazine-2-yl)-propyl)-4 -methylbenzamide, trifluoroacetic acid salt, used as anticarcinogenic or antiproliferative agents
12/18/2003US20030232831 Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
12/18/2003US20030232830 Non-covalent inhibitors of AmpC beta-lactamase
12/18/2003US20030232829 Treatments for nervous disorders
12/18/2003US20030232828 1-(aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands
12/18/2003US20030232827 Therapeutic compounds
12/18/2003US20030232825 Benzoxazine derivatives and uses thereof
12/18/2003US20030232824 Non-steroidal progesting
12/18/2003US20030232823 Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof
12/18/2003US20030232822 Ht3 receptor antagonists
12/18/2003US20030232819 Monoamine transporter inhibitors; used for early diagnosis and treatment of neurological and psychiatric conditions
12/18/2003US20030232817 Small molecules useful for the treatment of inflammatory disease
12/18/2003US20030232816 Benzimidazole derivatives
12/18/2003US20030232815 Non-peptidic cyclophilin binding compounds and their use
12/18/2003US20030232814 Novel compounds and their use
12/18/2003US20030232813 Novel amino substituted pyrimidinone derivatives
12/18/2003US20030232812 Microbiocides used to treat eye and skin infections
12/18/2003US20030232810 Bicyclic cyclohexylamines and their use as nmda receptor antagonists
12/18/2003US20030232809 Preventing or treating acute myocardial infarction, unstable angina and peripheral artery occlusion
12/18/2003US20030232807 Dietetic agents
12/18/2003US20030232806 Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them
12/18/2003US20030232805 Administering a dual serotonin/norepinephrine reuptake inhibitor or a triple monoamine reuptake inhibitor for serotonin/noradrenaline/ dopamine
12/18/2003US20030232804 Glycinamides as factor Xa inhibitors
12/18/2003US20030232803 Crystalline 1-methylcarbapenem derivatives
12/18/2003US20030232802 Aryl and heteroaryl sulfonates
12/18/2003US20030232801 Identification of compounds for the treatment or prevention of proliferative diseases
12/18/2003US20030232799 Using copper chelating compounds other than D-penicillamine, in particular polyamines such as triethylenetetramine or tetraethylenepentamine
12/18/2003US20030232798 Adrenal enzyme inhibitors
12/18/2003US20030232797 Useful as immunomodulating and antiinflammatory compounds and in treatment of cardiovascular disease and cancer
12/18/2003US20030232796 Nanoparticulate polycosanol formulations & novel polycosanol combinations
12/18/2003US20030232795 Administering selective estrogen receptor modulators that possesses tissue-specific ER agonist activity
12/18/2003US20030232794 Fused nitrogen heterocycle derivatives useful to inhibit cancer or sensitize cancer cells to chemotherapeutic agents, radiation or other anti-cancer treatments
12/18/2003US20030232793 Comprising hyperglycemia, insulin dependent diabetes mellitus, impaired glucose tolerance, hyperinsulinemia, insulin insensitivity, diabetes related diseases
12/18/2003US20030232792 Useful for male contraception, treatment of a variety of hormone-related conditions such as sexual disorders, prostate cancer
12/18/2003US20030232791 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
12/18/2003US20030232790 Dihydro-2h-napthalene-1-one inhibitors of ras farnesyl transferase
12/18/2003US20030232788 Inhibitors of interleukin-1 beta converting enzyme and related proteases
12/18/2003US20030232787 Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
12/18/2003US20030232785 O-sulphated bacterial polysaccharides and their use
12/18/2003US20030232784 Pyridine manganese amine complex macrocycle; treatment of rheumatoid arthritis
12/18/2003US20030232783 Partial and full agonists of A1 adenosine receptors
12/18/2003US20030232780 Composition comprising an immunomodulatory molecule, which molecule comprises an antigen conjugated to an polynucleotide that contains at least one immunostimulatory nucleotide sequence; for modulating an immune response in vertebrates
12/18/2003US20030232767 Activating cancerous cells response to therapeutic agents, by administering cisplatin or oxaliplatin, applying ionizing radiation and hydrogen peroxide
12/18/2003US20030232766 Combinatorial libraries of monosaccharides
12/18/2003US20030232765 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
12/18/2003US20030232763 Reducing blood glucose concentrations, weight loss, and treating diseases and conditions mediated by the cyclooxygenase-2 and 5-lipoxygenase enzymes; an enzyme inhibitors
12/18/2003US20030232749 Methods for SHP1 mediated neuroprotection
12/18/2003US20030232748 Insulin aspart and insulin detemir in a specific ratio; antidiabetic agent
12/18/2003US20030232744 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
12/18/2003US20030232741 Methods of treatment of glaucoma and other conditions mediated by NOS-2 expression via inhibition of the EGFR pathway
12/18/2003US20030232740 A polynucleotide sequence encoding Cathepsin Y or a amino acid sequence of cathepsin Y protein for identification of therapeutic agent for stroke
12/18/2003US20030232739 Pharmaceutical combinations comprising a NOS inhibitor and an NMDA receptor antagonist
12/18/2003US20030232738 Increasing JAK3 (Janus kinase) action in CD4+ T lymphocytes of the patient infected with human immunodeficiency virus (HIV), wherein such CD4+ T lymphocytes express CD4 that has been ligated by gp120 on human immunodeficiency virus
12/18/2003US20030232392 Comprises soluble liver antigen auto-antibodies; fusion proteins
12/18/2003US20030232118 Beverages containing plant sterols
12/18/2003US20030232102 Total glycosides of paeony, method to prepare the same and uses thereof
12/18/2003US20030232101 Topical formulations of resorcinols and cannibinoids and methods of use
12/18/2003US20030232100 Compositions for treatment of diseases arising from secretion of mast cell biochemicals
12/18/2003US20030232098 Ginkgo biloba and garlic with a zinc compound in a synergistic combination; tablets, capsules for oral administration; enables use of lower, non-toxic doses of zinc
12/18/2003US20030232097 Oily wax matrix suspension formulation comprising ibuprofen free acid and potassium salt of ibuprofen
12/18/2003US20030232094 Composition and method for the treatment of skin irritations
1 ... 5239 5240 5241 5242 5243 5244 5245 5246 5247 5248 5249 5250 5251 5252 5253 5254 5255 5256 5257 5258 5259 ... 7860